Weiss Multi-Strategy Advisers’s Travere Therapeutics TVTX Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-192,870	Closed	-$2.96M	–	731
2023 Q2	$2.96M	Buy	192,870 +11,052	+6%	+$201K	0.06%	395
2023 Q1	$4.09M	Buy	181,818 +31,818	+21%	+$676K	0.1%	297
2022 Q4	$3.15M	Buy	150,000 +52,500	+54%	+$1.11M	0.09%	302
2022 Q3	$2.4M	Buy	97,500 +12,758	+15%	+$330K	0.06%	376
2022 Q2	$2.05M	Buy	+84,742	New	+$2.13M	0.06%	379
2017 Q3	–	Sell	-10,000	Closed	-$194K	–	619
2017 Q2	$194K	Hold	10,000	–	–	0.01%	495
2017 Q1	$185K	Buy	+10,000	New	+$196K	0.01%	518

Other funds holding TVTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Weiss Multi-Strategy Advisers's TVTX Position: Q3 2023 in Review

Weiss Multi-Strategy Advisers sold out of Travere Therapeutics (TVTX) in Q3 2023, closing a stake of 192,870 shares — an estimated $2.96M sold.

Weiss Multi-Strategy Advisers first reported a position in TVTX in Q1 2017 and held it in 7 quarters. The position peaked at $4.09M in Q1 2023. 169 funds tracked by Wall St. Rank hold TVTX as of Q3 2023.

Weiss Multi-Strategy Advisers reported no remaining Travere Therapeutics position as of Q3 2023 after selling out during the quarter.
Weiss Multi-Strategy Advisers sold 192,870 Travere Therapeutics shares in Q3 2023, an estimated $2.96M.
Weiss Multi-Strategy Advisers first reported a position in Travere Therapeutics in Q1 2017 and held it in 7 quarters.
Weiss Multi-Strategy Advisers's Travere Therapeutics position peaked at $4.09M in Q1 2023.
169 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2023.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q3 2023, filed 14 Nov 2023.